Central nervous system specialist Neuraxpharm has announced that it is entering the cannabidiol business after agreeing to buy Swiss Trade Union, a Switzerland-based developer and distributor of natural CBD consumer products.
“The deal enables Neuraxpharm to enter the fast-growing CBD space and to build on its business of CNS-related products, including value added medicines, standard generics and consumer healthcare
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?